Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $30.27, for a total transaction of $6,054,000.00. Following the sale, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at $48,827,417.01. The trade was a 11.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Eric Venker also recently made the following trade(s):

• On Monday, April 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $29.59, for a total transaction of $5,918,000.00.
• On Tuesday, March 17th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $28.24, for a total transaction of $5,648,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV traded down $0.92 during midday trading on Friday, reaching $29.96. 5,873,872 shares of the stock were exchanged, compared to its average volume of 6,125,914. The company has a 50 day simple moving average of $28.46 and a 200 day simple moving average of $25.02. The stock has a market capitalization of $21.44 billion, a P/E ratio of -49.93 and a beta of 1.14. Roivant Sciences Ltd. has a twelve month low of $10.59 and a twelve month high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter last year, the firm earned ($0.29) EPS. On average, research analysts expect that Roivant Sciences Ltd. will post -1.06 earnings per share for the current year.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors have recently modified their holdings of the company. Morgan Stanley lifted its position in shares of Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares during the last quarter. Vanguard Group Inc. raised its stake in Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after acquiring an additional 3,254,113 shares in the last quarter. Rubric Capital Management LP raised its stake in Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after acquiring an additional 2,603,260 shares in the last quarter. State Street Corp raised its stake in Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after acquiring an additional 911,827 shares in the last quarter. Finally, UBS Group AG raised its stake in Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after acquiring an additional 15,645,836 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research report on Thursday. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research report on Thursday. TD Cowen raised their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Roivant Sciences in a research report on Friday, May 8th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.05.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.